Replacing cholesterol with sterol modified lipids results in improved liposomal stability

Abstract

Liposomal nanoparticles are excellent candidates for vaccine and drug delivery applications, including the delivery of mRNA vaccines. However, a central challenge is the liposomal stability under physiological conditions that often result in uncontrolled drug release. The development of stable and long-circulating liposomes is, therefore, needed for protecting the encapsulated payload from degradation and premature release. Traditionally, this issue has been addressed through the incorporation of cholesterol in liposomal compositions.